Epcoritamab + Gemcitabine + Oxaliplatin in R/R DLBCL Transplant Ineligible Patients Induces High Response Rate Even in Pts Failing CAR T Therapy

June 24, 2022 | Joshua Brody MD

Share on:

Joshua Brody, MD, evaluates the use of epcoritamab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL who are ineligible for transplant.

onclive rapid readouts logo